NHS Blood and Transplant

(redirected from NHSBT)

NHS Blood and Transplant

A special health authority created in 2005 by the merger of the National Blood Service and UK Transplant, which manages the national voluntary donation system for blood, tissues, organs and stem cells, turning donations into products that can be used safely to benefit patients. NHSBT supplies ±2 million units of blood/year to hospitals in England and north Wales. In 2010, it received 3,500 organ and 4,000 tissue donations and banked 2,200 cord blood units from across the UK.
References in periodicals archive ?
The comments from NHSBT come as a fouryear-old girl is starting school with a new heart.
The comments from NHSBT come as a four-year-old girl is starting school with a new heart.
Dr Sara Trompeter, of NHSBT, says: "Patients taking part can now potentially receive more finely matched blood.
sunbeds is "not solution" Dr Sara Trompeter, of NHSBT, says: "Patients taking part can now potentially receive more finely matched blood.
The NHSBT said that this Christmas more than 200,000 blood donors are needed to help hundreds of thousands of patients across the country.
And as hospitals need 7,000 units of blood each day to treat patients with chronic conditions like cancer and anaemia - along with people needing treatment for often life-threatening illnesses and injuries - NHSBT is encouraging new or returning donors to book an appointment.
Recent figures released by NHSBT showed Wales stands well below the UK average with just a 15.
Sally Johnson, NHSBT director of organ donation and transplantation, said: "We need a transformation in donor and family consent to organ donation because the UK's family refusal rate remains one of the highest in Europe.
NHSBT aims to recruit 100,000 new donors in 100 days to counteract this drop and protect future blood stocks.
The NHSBT statistics coincided with statistics released on the annual World Blood Donor Day on June 14th.
National Blood Week kicks off today and the NHSBT is urging the public to become donors and join the 4% of the population who currently give blood.
Tissue Regenix has the exclusive commercialisation rights to all data generated from the NHSBT trials, adding that originally NHSBT had the right to carry out pre-clinical and clinical evaluations using Tissue Regenix's dCELL technology for development purposes and the manufacture of human tissue derived clinical products for use by the NHS.